Bone turnover markers in the management of postmenopausal osteoporosis.
about
Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causalityBone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryAntiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women.Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis?Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension."Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial"Improved nutritional status and bone health after diet-induced weight loss in sedentary osteoarthritis patients: a prospective cohort study.Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state.The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women.The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitusAssessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).Socioeconomic status, race, and bone turnover in the Midlife in the US Study.Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized ratsEquilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.The clinical utility of bone marker measurements in osteoporosis.Functional investigation of bone implant viability using radiotracers in a new model of osteonecrosis.The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study.A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part II: 1-Yr Change, Long-Term Precision, and Least Significant Change.Interpretation and use of FRAX in clinical practice.Bone turnover markers: use in osteoporosis.A meta-analysis of reference markers of bone turnover for prediction of fracture.Novel assessment tools for osteoporosis diagnosis and treatment.Effects of alendronate on the peri-implant bone in rats.Stem cells applications in bone and tooth repair and regeneration: New insights, tools, and hopes.Assessment of vitamin D status and serum CrossLaps levels in adults with primary lactose malabsorption.A biochemical approach for assessing cutoffs at the age thresholds of 14 and 18 years: a pilot study on the applicability of bone specific alkaline phosphatase on an Italian sample.The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.Recommendations on the management of fragility fracture risk in women younger than 70 years.Effect of dimethyl sulfoxide on inhibition of post-ovariectomy osteopenia in rats.Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.Evaluation of bone mineral density (BMD) and indicators of bone turnover in patients with hemophilia.Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.Evaluating the efficacy of functional electrical stimulation therapy assisted walking after chronic motor incomplete spinal cord injury: effects on bone biomarkers and bone strength.Decreased bone turnover markers in children on long-term parenteral nutrition (PN) for intestinal failure (IF).Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing.Highly bioavailable nanocalcium from oyster shell for preventing osteoporosis in rats.Preliminary investigation of urine N-telopeptide concentration as a biomarker of bone resorption in dogs receiving glucocorticoids.The association between insulin-like growth factor 1 (IGF-1), IGF-binding proteins (IGFBPs), and the carboxyterminal propeptide of type I procollagen (PICP) in pre- and postmenopausal women with rheumatoid arthritis.
P2860
Q21245925-8EC4D6A1-AE5C-4E2F-8DEE-DAAE0783BDF1Q28066185-B44D54EC-3D55-481D-82B7-C332D2887A80Q28295416-1C40CA8F-A7D0-482B-9368-956EA4435F04Q33723041-6FF13708-4275-40E3-91D8-26944E75020EQ33811677-5C3865C4-210F-4EF5-B4E7-97943AFC3A20Q34041189-F1CE85D7-3173-4643-93B9-54725B22B991Q34096956-9141AE7A-9303-4471-8D81-74273C2AAB73Q34108237-AFE749A2-CA3A-428F-8FCB-4EF989C227AEQ34171858-FADE8798-6A10-4111-B254-7E54AC4D2A4BQ35100004-3AB5F5E4-1A87-47D2-937D-50ECF11CD9AAQ35153772-531D1BA1-EA50-4449-9B56-4D4F52B9226FQ35644141-C00471AD-57C6-462A-8882-560D471D833FQ35670217-322017FF-5F91-494A-89BA-818D2E555F3AQ35788591-EDFB6EB4-EFD0-4BBD-8C8C-6FFA62FA14EDQ35887609-109DD455-F5C8-4EF5-8296-66FFB56014EAQ36553571-DEB9DA4B-3F33-4873-9937-D49D8AAE13A4Q37153332-ED42F819-496B-4B9B-AE23-FD9E1AF3E133Q37329710-17686140-FA73-493C-AAFD-EA2F9B981AECQ37354704-D871E10E-9CF5-42D3-AA95-48CC497D91A0Q37388824-4FA99F79-DE3D-442E-882E-2E54F0FBD0B8Q37903748-3166E508-617C-4888-997E-34343B0BE0E7Q38016073-89F4A856-0079-418C-B5AB-CA88F732F38EQ38192911-453CC6C5-0E91-4410-A7EE-FFAC6753C996Q38216229-BD07A49B-A088-443E-9563-5248CFAD68F5Q38438261-2A7799DE-FDE3-4F30-8F1B-9BE64FA986F0Q38736047-0D3E056F-CB1F-4C65-910F-80777671E43EQ39819228-E2213659-AB65-4023-84C7-DBF9D52638C0Q40758884-A7937D51-04AA-4AB1-9E43-02E161D75907Q42263129-A278B797-3022-4720-A483-C1AA14F99F5CQ44278781-2AFA06C9-E34F-46A8-A002-0298E9A62B20Q44421391-EB365DBF-02AB-40A2-BD45-410021285AF3Q45155246-845871BD-84D1-42BF-A49C-A7DC5C111C8DQ45875787-52882387-186F-4F64-90F7-84AF0C694507Q46414905-212DE9DA-D8BB-4D0F-846F-D32A88716B21Q47655582-B0211A77-98D2-40CD-9688-79C300DED4ACQ47702723-FFAC4B3E-7EF5-45B8-84AB-1D0955AD0DB0Q50087627-05E847DA-6F46-4DFF-9A69-C363D3B935BBQ50666259-492EB0F3-382F-47E6-BCEE-D5E9007DCE14Q51023035-0F210BBE-3BA7-44DA-969D-02381D2E57EFQ51366871-49C4FD98-A866-4842-9590-BE7F17E7C33B
P2860
Bone turnover markers in the management of postmenopausal osteoporosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bone turnover markers in the management of postmenopausal osteoporosis.
@en
Bone turnover markers in the management of postmenopausal osteoporosis.
@nl
type
label
Bone turnover markers in the management of postmenopausal osteoporosis.
@en
Bone turnover markers in the management of postmenopausal osteoporosis.
@nl
prefLabel
Bone turnover markers in the management of postmenopausal osteoporosis.
@en
Bone turnover markers in the management of postmenopausal osteoporosis.
@nl
P2093
P1476
Bone turnover markers in the management of postmenopausal osteoporosis
@en
P2093
Alexandra Papaioaonnou
Andrew Don-Wauchope
Bassam A Nassar
Caroline Albert
David A Hanley
David Cole
Daylily S Ooi
Elaine Letendre
Jacques P Brown
John Krahn
P304
P356
10.1016/J.CLINBIOCHEM.2009.04.001
P577
2009-04-10T00:00:00Z